» Articles » PMID: 38844829

Unraveling the Relationship Between Serum Parathyroid Hormone Levels and Trabecular Bone Score: a Cross-sectional Study

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jun 6
PMID 38844829
Authors
Affiliations
Soon will be listed here.
Abstract

The TBS is a new method for clinicians to assess the bone quality. It is directly related to the mechanical strength of bone and helps predict fracture risk. The present analysis aimed to investigate the associations between serum PTH levels and TBS by analyzing data from the National Health and Nutrition Examination Survey (NHANES). A total of 3516 participants from the NHANES 2005-2006 were included in this cross-sectional study. The independent variable was serum PTH, and the outcome variable was TBS. The associations of serum PTH levels with TBS were examined using multivariable linear regression models. After adjusting for covariates, there was a negative association between serum PTH level and TBS (β = - 0.0034; 95% confidence interval, - 0.0050 to - 0.0017). However, in the subgroup analysis stratified by gender, race, and age, this association became negative only in Non-Hispanic White (β =  - 0.0047, 95% CI:  -  0.0071 to  -  0.0048) and young people (age < 60) (β = - 0.0036, 95% CI: - 0.0057, - 0.0016), regardless of gender. In addition, the association of serum PTH with TBS was an U-shaped curve, with a point of inflection at 6.71 pmol/L. This study showed that serum PTH level was negatively associated with TBS. Maintaining PTH levels in a lower reasonable clinical range may be beneficial to bone health, especially for young non-Hispanic white.

Citing Articles

Effects of Teriparatide and Alendronate on Functional Recovery from Spinal Cord Injury and Postinjury Bone Loss.

Wang S, Zhu J, Feng Y, Hua Y, You G, Su J Biomedicines. 2025; 13(2).

PMID: 40002755 PMC: 11852434. DOI: 10.3390/biomedicines13020342.


Bilateral femoral neck fractures in pregnancy suggestive of transient osteoporosis of the hip in a patient with hyperparathyroidism: a case report.

Blake R, Melemai V, Fitzpatrick B, Hubbard D, Dietz M, Watkins C Osteoporos Int. 2024; 36(2):333-337.

PMID: 39715915 DOI: 10.1007/s00198-024-07346-4.

References
1.
Martineau P, Leslie W, Johansson H, Oden A, McCloskey E, Hans D . Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. J Bone Miner Res. 2017; 32(7):1568-1574. DOI: 10.1002/jbmr.3124. View

2.
Rosen C . Insulin-like growth factor-I and parathyroid hormone: potential new therapeutic agents for the treatment of osteoporosis. Expert Opin Investig Drugs. 2005; 6(9):1193-8. DOI: 10.1517/13543784.6.9.1193. View

3.
Kurland E, Cosman F, McMahon D, Rosen C, Lindsay R, Bilezikian J . Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85(9):3069-76. DOI: 10.1210/jcem.85.9.6818. View

4.
Parisien M, Silverberg S, Shane E, Dempster D, Bilezikian J . Bone disease in primary hyperparathyroidism. Endocrinol Metab Clin North Am. 1990; 19(1):19-34. View

5.
Patel K, Salama S, Cottreau J . Osteoporosis: A Review of Novel Agents. Orthop Nurs. 2022; 41(6):428-433. DOI: 10.1097/NOR.0000000000000899. View